Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial registered on ANZCTR
Registration number
ACTRN12623000287639
Ethics application status
Approved
Date submitted
9/03/2023
Date registered
17/03/2023
Date last updated
16/06/2024
Date data sharing statement initially provided
17/03/2023
Date results information initially provided
16/06/2024
Type of registration
Prospectively registered
Titles & IDs
Public title
Effectiveness of herbal formulations for stress
Query!
Scientific title
A randomised placebo-controlled trial investigating effectiveness of two herbal combinations for short-term stress management in healthy adults
Query!
Secondary ID [1]
309160
0
None
Query!
Universal Trial Number (UTN)
U1111-1289-5575
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Stress
329283
0
Query!
Condition category
Condition code
Alternative and Complementary Medicine
326235
326235
0
0
Query!
Herbal remedies
Query!
Mental Health
326236
326236
0
0
Query!
Anxiety
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment Arm 1 - Herbal tablet containing: Ziziphus jujuba var. spinosa (Ziziphus), Passiflora incarnata (Passionflower), Melissa officinalis (Lemon balm) and Matricaria chamomilla (Chamomile). Three tablets daily, orally, in divided doses, for 21 days.
Treatment Arm 2 - Herbal tablet containing: Withania somnifera (root) and Crocus sativus (stigma). Two tablets daily, orally, in divided doses, for 21 days.
Participants in Treatment Arm #1 will be directed to take , one in the morning, one in middle of day, and one in the evening. Participants in Treatment Arm #2 will be directed to take two tablets, orally, daily, one in the morning, and one in the evening. Compliance will be assessed through returned tablet count on completion of study.
Query!
Intervention code [1]
325609
0
Treatment: Drugs
Query!
Comparator / control treatment
Placebo tablets containing microcrystaline cellulose
Query!
Control group
Placebo
Query!
Outcomes
Primary outcome [1]
334107
0
Change in stress, depression and anxiety indices assessed using the Depression, anxiety, stress scale (DASS-21). Analysed as a composite outcome (change in overall DASS-21 score)
Query!
Assessment method [1]
334107
0
Query!
Timepoint [1]
334107
0
Baseline and day 21 after treatment randomisation
Query!
Secondary outcome [1]
419381
0
Change in stress levels assessed using the Perceived Stress Scale (PSS)
Query!
Assessment method [1]
419381
0
Query!
Timepoint [1]
419381
0
Baseline and day 21 after treatment randomisation
Query!
Secondary outcome [2]
419382
0
Change in sleep assessed using PROMIS Sleep Scale - adult short-form (PROMIS)
Query!
Assessment method [2]
419382
0
Query!
Timepoint [2]
419382
0
Baseline and day 21 after treatment randomisation
Query!
Secondary outcome [3]
419383
0
Change in anxiety assessed using Zung Self-Rating Anxiety Scale (Zung) (assessed in Treatment Arm #1 only)
Query!
Assessment method [3]
419383
0
Query!
Timepoint [3]
419383
0
Baseline and day 21 after treatment randomisation
Query!
Secondary outcome [4]
419384
0
Patient Global Impression of Change
Query!
Assessment method [4]
419384
0
Query!
Timepoint [4]
419384
0
Baseline and day 21 after treatment randomisation
Query!
Eligibility
Key inclusion criteria
- - Healthy adults (18-75 years)
- - Any allowable prescription medication use by participants must be stable for four weeks or more prior to trial entry
- - Score of 13 or more on the Perceived Stress Scale (PSS-10)
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
75
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
Yes
Query!
Key exclusion criteria
- - Diagnosed depression or anxiety for which person is taking medication or has ceased taking medication within the last four weeks
- - Diagnosed with any of the following medical conditions: cancer (if active within last 5 years and excepting skin cancer), liver or kidney disease, neurological disease
- - Currently unwell with acute infection or fever
- - Having contracted confirmed Covid-19 in the four weeks prior to enrolment
- - In poor general health
- - Taking any of the following medications: anti-depressants; any type of neuro-active medications, i.e. mood stabilisers, stimulants, anti-psychotics; warfarin or anti-coagulant medications, cyclosporin
- - Current use of any herbal medicine or nutrients targeted for mood, stress or mental health (eligibility of participants taking any supplements will be at discretion of enrolling practitioner)
- - Pregnant or breastfeeding or planning pregnancy
- - Allergy/sensitivity to study drugs or their formulations
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Before randomisation, participants will be assessed by naturopathic clinicians and allocated to one of two treatment arms based on their initial presentation. Persons presenting with a mild to moderate level of anxiety will be allocated into Treatment Arm #1 and randomised to receive Active or Placebo study medication in a 2:1 ratio. Persons presenting without any significant anxiety symptoms will be allocated into Treatment Arm #2 and randomised to receive Active or Placebo study medication in a 2:1 ratio. Clinicians will be blinded to treatment allocation through the use of pre-randomised numbered study medication bottles.
The prescribing naturopath will be aware of the group allocation, i.e. to Treatment Arm #1 or Treatment Arm #2, but will be unaware of whether the participant has been allocated to Active or Placebo tablets (double-blind).
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Simple randomisation using a randomisation table created by computer software (i.e. computerised sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 2
Query!
Type of endpoint/s
Efficacy
Query!
Statistical methods / analysis
An a priori power analysis was undertaken to estimate the required sample size. We predicted a 20% between group difference in DASS-21 mean scores between active and placebo groups with a 2:1 treatment ratio. Assuming a power of 80%, a type 1 error rate (alpha) of 5%, and a 10% drop-out rate, the total number of participants to find an effect was estimated as 50 for each Treatment Arm (35 Active and 15 Placebo for each treatment arm). Therefore, a total of 100 participants will be enrolled.
Analysis of data will be conducted on final locked dataset, with blinding to group allocations. Data analysis will be conducted by an independent statistician.
Treatment Arm #1 and #2 will be analysed separately for changes and scores also analysed as a complete group for all questionnaires except Zung SAS (which will be administered to Treatment Arm #1 only). Changes for the primary outcome will be calculated from baseline to week 3 and compared to placebo using T-tests and general linear regression (GLM) models. The secondary outcomes of PSS, PROMIS Sleep scale and Zung SAS will be calculated from baseline to week 3 and compared to placebo using T-tests and general linear regression (GLM) models. Adverse events will be assessed qualitatively and compared to placebo. All tests of treatment effects will be conducted using a two-sided alpha level of 0.05 and 95% confidence intervals.
Query!
Recruitment
Recruitment status
Stopped early
Query!
Data analysis
Data analysis is complete
Query!
Reason for early stopping/withdrawal
Participant recruitment difficulties
Query!
Date of first participant enrolment
Anticipated
17/04/2023
Query!
Actual
17/04/2023
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
27/09/2023
Query!
Date of last data collection
Anticipated
Query!
Actual
11/10/2023
Query!
Sample size
Target
100
Query!
Accrual to date
Query!
Final
94
Query!
Recruitment in Australia
Recruitment state(s)
ACT,NSW,NT,QLD,SA,TAS,WA,VIC
Query!
Funding & Sponsors
Funding source category [1]
313360
0
Commercial sector/Industry
Query!
Name [1]
313360
0
Integria Healthcare (Australia) Pty Ltd.
Query!
Address [1]
313360
0
Building 5, Freeway Office Park, 2728 Logan Rd, Eight Mile Plains, Qld 4113
Query!
Country [1]
313360
0
Australia
Query!
Primary sponsor type
Commercial sector/Industry
Query!
Name
Integria Healthcare (Australia) Pty Ltd.
Query!
Address
Building 5, Freeway Office Park, 2728 Logan Rd, Eight Mile Plains, Qld 4113
Query!
Country
Australia
Query!
Secondary sponsor category [1]
315123
0
None
Query!
Name [1]
315123
0
Query!
Address [1]
315123
0
Query!
Country [1]
315123
0
Query!
Ethics approval
Ethics application status
Approved
Query!
Ethics committee name [1]
312581
0
National Institute of Integrative Medicine
Query!
Ethics committee address [1]
312581
0
11 Burwood Rd, Hawthorn VIC 3122
Query!
Ethics committee country [1]
312581
0
Australia
Query!
Date submitted for ethics approval [1]
312581
0
17/01/2023
Query!
Approval date [1]
312581
0
20/03/2023
Query!
Ethics approval number [1]
312581
0
Query!
Summary
Brief summary
This will be a blinded, placebo-controlled clinical trial conducted within natural medicine clinics. Initial screening and consenting of participants will be conducted by the Co-Investigator and participants allocated to individual naturopathic clinicians for assessment interviews. The study includes two active treatment options and a placebo control. Participants will be allocated into Treatment Arm #1 or Treatment Arm #2 based on their initial clinical presentation, categorised into either an ‘anxiety-driven’ stress type (Treatment Arm #1) or a ‘non-anxiety driven’ stress type (Treatment Arm #2).
Participants will be tested for stress, depression and anxiety indices at baseline and at day 21 for changes in these areas.
Query!
Trial website
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
125170
0
Dr Elizabeth Steels
Query!
Address
125170
0
Registered business address: 188 James Street, New Farm, Qld, 4005
Query!
Country
125170
0
Australia
Query!
Phone
125170
0
+61 428983280
Query!
Fax
125170
0
Query!
Email
125170
0
[email protected]
Query!
Contact person for public queries
Name
125171
0
Dr Elizabeth Steels
Query!
Address
125171
0
Registered business address: 188 James Street, New Farm, Qld, 4005
Query!
Country
125171
0
Australia
Query!
Phone
125171
0
+61 428983280
Query!
Fax
125171
0
Query!
Email
125171
0
[email protected]
Query!
Contact person for scientific queries
Name
125172
0
Dr Elizabeth Steels
Query!
Address
125172
0
Registered business address: 188 James Street, New Farm, Qld, 4005
Query!
Country
125172
0
Australia
Query!
Phone
125172
0
+61 428983280
Query!
Fax
125172
0
Query!
Email
125172
0
[email protected]
Query!
Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
No
Query!
No/undecided IPD sharing reason/comment
Data is commercial-in-confidence.
Query!
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
Documents added manually
No documents have been uploaded by study researchers.
Documents added automatically
No additional documents have been identified.
Download to PDF